T3

T3 is the pharmaceutical designation for triiodothyronine, one of the two principal hormones released by the thyroid gland. Chemically it is an iodine-bearing derivative of the amino acid tyrosine that carries three iodine atoms on its ring structure, and it is dispensed as the salt liothyronine sodium under brand names such as Cytomel. Within the body, T3 represents the active thyroid signal, whereas the more abundant thyroxine (T4) functions largely as a reservoir that peripheral tissues convert into T3 as required ^[1][4].

The primary medical use of liothyronine is hormone replacement in hypothyroidism, and because it acts quickly it is favored in myxedema coma, a life-threatening state of profound thyroid failure ^[1][2]. Its comparatively rapid clearance is also exploited before radioactive-iodine therapy for thyroid cancer, since a shorter hormone-withdrawal window is needed than with thyroxine ^[1]. Beyond thyroid disease, T3 has been studied as an augmenting agent in mood disorders; a meta-analysis of controlled trials found that adding it to tricyclic antidepressants tended to accelerate the treatment response, with the benefit being more pronounced among women ^[3].

Liothyronine entered clinical use in the 1950s and is supplied both as oral tablets and as an injectable preparation reserved for emergencies ^[1]. It is a prescription-only medicine in countries including the United States, the United Kingdom, and Canada, and is available as an inexpensive generic ^[1]. Product labeling warns against using thyroid hormone as a weight-loss aid in people with normal thyroid function, because excessive amounts can produce serious cardiac and metabolic toxicity, a hazard that is heightened when the hormone is combined with stimulant appetite suppressants ^[1]. Controlled single-dose studies confirm that its influence on the heart and on pituitary feedback follows the rise in circulating hormone by a matter of hours ^[4].

T3 (liothyronine) is a potent thyroid hormone, and excess quickly produces hyperthyroid effects: palpitations, arrhythmia, anxiety, tremor, heat intolerance, and weight loss, with bone loss on chronic overuse. It is especially risky in cardiac disease and requires medical supervision and lab monitoring.

Thyroid hormone changes how several other drugs behave, and the anticoagulant interaction is the one that draws blood. T3 accelerates hepatic clearance of the vitamin K-dependent clotting factors, so warfarin and related coumarins become more potent as thyroid status shifts, and INR can drift upward for weeks after a change in hormone dose. Insulin and oral hypoglycemics move the other way, since restoring a euthyroid state raises metabolic demand and glucose requirements change with it.

Absorption is easy to block. Cholestyramine and colesevelam, calcium carbonate, ferrous sulfate, sucralfate and aluminum antacids bind liothyronine in the gut and cut how much reaches the circulation. That happens on contact in the lumen rather than through metabolism, so it depends entirely on timing. Proton pump inhibitors blunt absorption more modestly.

On the cardiac side, T3 adds to the chronotropic effect of sympathomimetics such as pseudoephedrine and albuterol, and it raises the arrhythmia risk of digoxin and of catecholamines given during anesthesia. Phenytoin, carbamazepine and rifampin induce hepatic metabolism and pull circulating hormone down.

Checking a whole stack? Run it through interactions + stacks.

Triiodothyronine, the hormone marketed generically as liothyronine, was identified in 1952 by Jack Gross and Rosalind Pitt-Rivers, who demonstrated that this triiodinated thyronine was a distinct and highly active thyroid hormone circulating alongside thyroxine. The discovery clarified that thyroxine served largely as a precursor that the body converts into the more potent T3, reshaping the understanding of thyroid physiology.

A synthetic form was subsequently developed for clinical use, providing the receptor-active hormone directly without the need for peripheral conversion. Over the following decades liothyronine found roles in the treatment of hypothyroidism and myxedema coma, in preparing thyroid-cancer patients for radioiodine therapy, and as an occasional augmenting agent in difficult-to-treat depression. Because of its faster onset and shorter duration compared with thyroxine, it has generally been used in more specialized situations than the widely prescribed storage hormone.

T3 is respected as the most metabolically active thyroid hormone and as a fast-acting, potent option when a rapid or direct thyroid effect is desired. Endocrinologists value liothyronine in specific settings such as myxedema coma and the preparation of thyroid-cancer patients, and some patients who feel incompletely well on thyroxine alone report benefit from combination approaches. In psychiatry it has a long-standing and favorably regarded role as an inexpensive augmenting agent that can improve mood in some people with treatment-resistant depression. Its honest trade-offs follow from its very potency: it acts quickly and briefly, which can make steady dosing more demanding, and excess can push the body toward a hyperthyroid state with effects on heart rate. Used thoughtfully, it remains a valuable and time-tested tool within thyroid and mood medicine.